1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 15,800 | 16,400 | 25.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Sartorius Stedim Biotech S.A. GAAP EPS of €0.91, revenue of €761.5M | 3 | Seeking Alpha | ||
| Do | Sartorius Stedim Biotech SA Q1 Profit Rises | 261 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech SA (DIM.PA) released earnings for its first quarter that Increases, from the same period last yearThe company's bottom line came in at EUR88.1 million... ► Artikel lesen | |
| Do | Sartorius Stedim Biotech Q1 Profit Rises On Revenue Growth; Confirms FY26 Outlook | 242 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech SA (SDMHF) reported Thursday higher profit and revenues in its first quarter. Further, the firm maintained its fiscal 2026 outlook.René Fáber, CEO... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH SA ADR Aktie jetzt für 0€ handeln | |||||
| Do | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026 | 261 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Quarter Results
Sartorius Stedim Biotech reports robust first-quarter results for fiscal 2026 23-Apr-2026 / 07:00 CET/CEST
Aubagne... ► Artikel lesen | |
| 02.04. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 293 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 01.04. | Dividendenbekanntmachungen (01.04.2026) | 8.734 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AECOM US00766T1007 0,31 USD 0,2683 EUR AIR PRODUCTS & CHEMICALS INC US0091581068 1,81 USD 1,5666 EUR ARB CORPORATION LIMITED AU000000ARB5 0... ► Artikel lesen | |
| 24.03. | Sartorius Stedim Biotech SA: Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. | 504 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. 24-March-2026 / 15:32 CET/CEST
Aubagne... ► Artikel lesen | |
| 17.03. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets | 676 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Forecast
Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets 17-March-2026 / 07:03... ► Artikel lesen | |
| 02.03. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 493 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 16.02. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech releases Universal Registration Document 2025 | 629 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2025 16-Feb-2026 / 09:13 CET/CEST
Aubagne, France... ► Artikel lesen | |
| 06.02. | Board of Directors of Sartorius Stedim Biotech S.A. resolves dividend proposal of 0.69 euros | 484 | Dow Jones News | DJ Board of Directors of Sartorius Stedim Biotech S.A. resolves dividend proposal of 0.69 euros
Sartorius Stedim Biotech SA / Key word(s): Dividend
Board of Directors of Sartorius Stedim Biotech... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech FY25 Results Climb; Sees Growth In FY26, Beyond | 501 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech S.A. (SRTOY, SDMHF, DIM.PA) reported Tuesday higher profit and sales revenues in fiscal 2025, with growth in all regions. Looking ahead for fiscal... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook | 892 | Dow Jones News | DJ Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook
Sartorius Stedim Biotech SA / Key word(s): Preliminary Results
Sartorius Stedim Biotech... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech S.A. Non-GAAP EPS of €4.40, revenue of €2.97B; initates FY26 outlook | 4 | Seeking Alpha | ||
| 02.02. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 393 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 12.01. | Goldman Sachs stuft Sartorius Stedim Biotech nach Kursrallye herab | 5 | Investing.com Deutsch | ||
| 12.01. | Goldman Sachs downgrades Sartorius Stedim Biotech stock rating after recent rally | 3 | Investing.com | ||
| 06.01. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 929 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 05.01. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 525 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 03.12.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 539 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCELLX | 115,03 | -0,01 % | Arcellx, Inc. - 10-K/A, Annual Report | ||
| SUMMIT THERAPEUTICS | 22,080 | -0,81 % | Stifel reiterates Summit Therapeutics stock rating on trial data | ||
| QIAGEN | 32,580 | +0,12 % | Aktien New York Ausblick: Moderate Gewinne - Lage in Nahost sorgt für Vorsicht | NEW YORK (dpa-AFX) - Am US-Aktienmarkt werden am Dienstag zum Handelsstart moderate Gewinne erwartet. Angesichts der unsicheren Lage in Nahost dominiert - wie bereits zum Wochenstart - die Vorsicht.... ► Artikel lesen | |
| ERASCA | 21,490 | -4,40 % | Erasca, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 11,260 | +1,67 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| BEAM THERAPEUTICS | 27,105 | -10,13 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,130 | +0,33 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,760 | -0,43 % | Stifel reiterates Tango Therapeutics stock rating on combo potential | ||
| ENVERIC BIOSCIENCES | 5,020 | +24,57 % | What's Going On With Enveric Biosciences Stock On Friday? | ||
| EVOTEC | 5,350 | -0,93 % | RBC stuft Evotec auf 'Outperform' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat die Einstufung für Evotec auf "Outperform" mit einem Kursziel von 10 Euro belassen. Charles Weston passte seine Prognosen und das Bewertungsmodell... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,700 | -1,80 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| NUVALENT | 104,53 | -3,28 % | Nuvalent präsentiert AACR-Daten vor PDUFA-Entscheid im September | ||
| BIONTECH | 90,15 | +0,22 % | Durchbruch in der Psychotherapie: Emyria meldet 50% Remission - Ein neuer "BioNTech-Moment" für die Mental-Health-Branche? | ||
| FIRST TRACKS BIOTHERAPEUTICS | 18,160 | -4,47 % | AnaptysBio, Inc.: Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately... ► Artikel lesen | |
| MAPLIGHT THERAPEUTICS | 29,760 | +2,62 % | MapLight Therapeutics, Inc.: MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected to reach target enrollment (n=300) in April 2026, with topline results expected in the third quarter of 2026Phase 2 IRIS trial for ML-004... ► Artikel lesen |
SARTORIUS STEDIM BIOTECH SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -11,36 % bei einem Aktienkurs von 15,600 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SARTORIUS STEDIM BIOTECH SA ADR finden Sie auf Wallstreet Online.